About KaliVir

Dr. Helena Chaye is Chief Executive Officer of KaliVir Immunotherapeutics and has over 25 years of experience in the biotechnology industry, with a sustained focus on the development of oncolytic immunotherapies. She has held senior leadership roles across corporate strategy, operations, business development, and intellectual property management, and has experience guiding organizations through scientific, regulatory, and corporate development milestones.

Prior to KaliVir, Dr. Chaye served as Chief Executive Officer of Western Oncolytics, following roles as Acting Chief Operating Officer and Chief Business Officer, where she supported corporate strategy, operational execution, and the advancement of clinical and preclinical programs. Earlier, she served as Chief Business Officer at SillaJen Biotherapeutics, where she was responsible for corporate and business development strategy, R&D planning, and intellectual property. She previously held senior roles at Jennerex Biotherapeutics and MediGene.

Dr. Chaye holds a B.S. in Biochemistry and a Ph.D. in Genetics from the University of British Columbia and a J.D. from Dalhousie University.

Dr. Stephen Thorne is Chief Scientific Officer and co-founder of KaliVir Immunotherapeutics and has played a foundational role in the field of oncolytic immunotherapy. His work has contributed to the scientific underpinnings of multiple oncolytic immunotherapy platforms and informed translational and clinical development strategies.

Dr. Thorne has co-founded several biotechnology companies focused on oncolytic immunotherapies, including Western Oncolytics, Duo Oncology, BioEclipse Therapeutics, and Jennerex. He previously served as Associate Professor of Cell Biology and Immunology at the University of Pittsburgh.

Dr. Thorne has authored more than 100 peer-reviewed scientific publications, including articles in journals such as Nature Medicine, Cancer Cell, Clinical Cancer Research, and Molecular Therapy. He completed postdoctoral training at Cancer Research UK, the University of Surrey, and Stanford University. Dr. Thorne received his B.A. from the University of Oxford and his Ph.D. from Imperial College London.

Dr. James Burke is Chief Medical Officer of KaliVir Immunotherapeutics and has more than 20 years of experience leading global clinical development programs in gene therapy and immuno-oncology, with a particular focus on oncolytic immunotherapies.

Most recently, Dr. Burke served as Chief Medical Officer at CG Oncology, where he led the preclinical, translational, and clinical development of cretostimogene grenadenorepvec (CG0070) from first-in-human Phase 1 studies through pivotal Phase 3 trials and supported the Company’s subsequent NASDAQ initial public offering. His experience includes clinical strategy, trial execution, regulatory engagement, and preparation for registrational pathways. In addition to clinical development, Dr. Burke has supported medical affairs activities and business development efforts within immuno-oncology and oncolytic immunotherapy therapeutics areas.

Dr. Burke holds a B.S. in Biochemistry and Cell Biology from the University of California, San Diego, an M.D. from Georgetown University, and completed fellowship training in hematology and oncology at the University of California, San Francisco.

Schond Greenway is Chief Financial Officer of KaliVir Immunotherapeutics and has more than 25 years of experience in corporate finance and capital markets leadership across emerging and public biotechnology companies. In addition to his capital markets expertise, Mr. Greenway has built and overseen financial/accounting and IT functions, and supported enterprise risk management, while aligning capital strategy with clinical and corporate inflection points.

Prior to KaliVir, Mr. Greenway served as CFO of Definium (formerly Mind Medicine), Avalo Therapeutics, and held senior finance and strategy leadership roles at Mesoblast Ltd, Halozyme Therapeutics, and DURECT Corporation (acquired by Bausch Health). He began his career in investment banking at Morgan Stanley and later served as a Vice President, healthcare desk research analyst at Barclays Capital.

Across his investment banking and operating roles, Mr. Greenway has advised on transactions totaling more than $30 billion and has secured over $1.5 billion in growth equity, private capital, and strategic R&D funding for biopharmaceutical companies.

Mr. Greenway holds a B.S. in Computer Information Systems from Florida A&M University and an MBA from the Darden School of Business at the University of Virginia.

Adina Pelusio is Chief Development Officer at KaliVir Immunotherapeutics and has experience leading global clinical development programs across oncolytic immunotherapies, cell therapies, cancer vaccines, and other complex biologic products requiring heightened regulatory oversight.

Prior to KaliVir, Ms. Pelusio served as Senior Vice President of Clinical Operations at Turnstone Biologics, where she led the global execution of the company’s clinical development strategy across cell therapy and oncolytic immunotherapy programs. She previously held senior clinical operations roles at SillaJen Biotherapeutics and Jennerex Biotherapeutics.

Ms. Pelusio holds a B.S. from the University of Miami, an M.S. in Medical Microbiology with a focus on virology and immunology from the University of Florida, and an M.P.H. in Epidemiology and Biostatistics from Harvard University.

Dr. Ursula Fritsch is Chief Regulatory Officer at KaliVir Immunotherapeutics and has more than 30 years of experience in global regulatory affairs and quality assurance across all phases of drug development.

Dr. Fritsch has led regulatory strategy from pre-IND through NDA and BLA submission and commercialization and has overseen regulatory submissions for over [X] products. She has experience directing regulatory programs for multiple oncolytic immunotherapy companies, including Onyx Pharmaceuticals, Jennerex Biotherapeutics, SillaJen, and CG Oncology, where she supported FDA alignment on pivotal and registrational study designs.

Her prior roles include Vice President of Global Regulatory Affairs and Compliance at Anthera Pharmaceuticals and senior regulatory leadership positions at Peninsula Pharmaceuticals and Genentech.

Dr. Fritsch holds a B.A. from the University of Nebraska and a PharmD from Creighton University.

Paul Youm is Executive Vice President of Business Development and Corporate Affairs at KaliVir Immunotherapeutics and has experience supporting strategic transactions, partnerships, and alliance management within the life sciences sector. Mr. Youm has experience working with business development teams on the licensing of technology, from early-stage partnership discussions through contract negotiation, alliance kickoff, and ongoing operational execution.

Prior to joining KaliVir, Mr. Youm held senior roles including President of YNY Associates, Executive Director of Business Development at ROKIT Healthcare, and In-House Counsel and Business Development Director at SillaJen Biotherapeutics. He has been involved in venture and pre-IPO financings, IPO diligence, licensing and collaboration agreements, alliance management, and corporate governance.

Mr. Youm is licensed with the Korean Bar Association and holds a B.S. in Biomedical Engineering from Duke University and a Master of Laws degree from Sogang University School of Law in Seoul.

Dr. Helena Chaye is Chief Executive Officer of KaliVir Immunotherapeutics and has over 25 years of experience in the biotechnology industry, with a sustained focus on the development of oncolytic immunotherapies. She has held senior leadership roles across corporate strategy, operations, business development, and intellectual property management, and has experience guiding organizations through scientific, regulatory, and corporate development milestones.

Prior to KaliVir, Dr. Chaye served as Chief Executive Officer of Western Oncolytics, following roles as Acting Chief Operating Officer and Chief Business Officer, where she supported corporate strategy, operational execution, and the advancement of clinical and preclinical programs. Earlier, she served as Chief Business Officer at SillaJen Biotherapeutics, where she was responsible for corporate and business development strategy, R&D planning, and intellectual property. She previously held senior roles at Jennerex Biotherapeutics and MediGene.

Dr. Chaye holds a B.S. in Biochemistry and a Ph.D. in Genetics from the University of British Columbia and a J.D. from Dalhousie University.

Dr. Stephen Thorne is Chief Scientific Officer and co-founder of KaliVir Immunotherapeutics and has played a foundational role in the field of oncolytic immunotherapy. His work has contributed to the scientific underpinnings of multiple oncolytic immunotherapy platforms and informed translational and clinical development strategies.

Dr. Thorne has co-founded several biotechnology companies focused on oncolytic immunotherapies, including Western Oncolytics, Duo Oncology, BioEclipse Therapeutics, and Jennerex. He previously served as Associate Professor of Cell Biology and Immunology at the University of Pittsburgh.

Dr. Thorne has authored more than 100 peer-reviewed scientific publications, including articles in journals such as Nature Medicine, Cancer Cell, Clinical Cancer Research, and Molecular Therapy. He completed postdoctoral training at Cancer Research UK, the University of Surrey, and Stanford University. Dr. Thorne received his B.A. from the University of Oxford and his Ph.D. from Imperial College London.

Tom Leonard is a serial entrepreneur who has founded and led several technology companies. He co-founded and led Clear Voice Research, Red Rocket Solutions, Encore Development and TML Systems, and previously served as Chief Operating Officer and Chief Information Officer of DMEautomotive. He has served on the boards of Western Oncolytics, Caretta Data and DMEautomotive.

Earlier in his career, Mr. Leonard was a General Manager at Symantec and a Software Architect at Harris Corporation. He holds a B.S. and an M.S. in Computer Science from Florida State University.

Dr. Jon Wigginton has more than 25 years of experience in oncology and immuno-oncology drug development. He is President of Research and Development at Bright Peak Therapeutics. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development at MacroGenics and as Chief Medical Officer of Cullinan Oncology, and founded Bethesda Biomedical Consulting.

Previously, Dr. Wigginton was Therapeutic Area Head of Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb, where he led early clinical development of the company’s immuno-oncology portfolio, including anti-PD-1, anti-PD-L1 and anti-CTLA-4/anti-PD-1 combinations. Before that, he was Director of Clinical Oncology at Merck Research Laboratories and held several positions at the National Cancer Institute’s Center for Cancer Research, including Head of the Investigational Biologics Section in the Pediatric Oncology Branch.

Dr. Wigginton is a past President of the Society for Immunotherapy of Cancer (SITC). He received a B.S. in Biology and an M.D. from the University of Michigan.

Kurt Rote co-founded Western Oncolytics, KaliVir’s predecessor, and led the company through technology licensing from the University of Pittsburgh, seed and Series A fundraising, and its partnership with Pfizer.

He previously served as Head of Product Development and Marketing at Biognosys AG and held strategy and business development roles at Holcim US. Mr. Rote holds an M.B.A. from IMD (International Institute for Management Development) in Switzerland and a B.S.E. from Duke University.

Woo Young Kim joined KaliVir’s Board of Directors in August 2026 and represents Company K Partners, which led KaliVir’s Series A extension financing.

Kwang Ha Jung joined KaliVir’s Board of Directors in August 2026 and represents SV Investment, a participant in KaliVir’s Series A extension financing.

JP Hong joined KaliVir’s Board of Directors in August 2026 and represents Flexus Partners, a participant in KaliVir’s Series A extension financing.